Patrick F. Timmins

https://assets.montefioreeinstein.org/profiles/images/Timmins_Patrick_MD_2x.jpg

First Name

Patrick

Last Name

Timmins

NPI

1942297080

Faculty ID

7152

CMO Specialties

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

48645

Biography

<p>Patrick F. Timmins III, MD, FACOG, FACS, is an attending physician at Montefiore Einstein and Vice Chair, Legislative Affairs at our Albert Einstein College of Medicine. Dr. Timmins addresses the individual needs and demands of patients in a warm and caring environment, providing a full range of gynecologic oncology services, including advanced gynecologic surgery, robotic surgery, chemotherapy treatment and palliative care.</p><p>After receiving his Bachelor of Science in biochemistry at The Ohio State University College of Biological Sciences in 1988, Dr. Timmins earned his Doctor of Medicine, cum laude, at the same institution in 1992. He completed his obstetrics and gynecology residency at Magee-Womens Hospital, University of Pittsburgh, in 1996, followed by a gynecologic oncology fellowship at Montefiore Einstein in 1999.</p><p>Dr. Timmins&rsquo; research focuses on recruiting and facilitating patients&rsquo; entry into clinical trials, patient outcomes, as well as mentoring young investigators. He has been principal investigator and co-principal investigator on multiple research projects and his work has been published in numerous peer-reviewed publications and abstracts. He has been a reviewer for Gynecologic Oncology for multiple years.</p><p>Dr. Timmins is board certified by the American Board of Obstetrics and Gynecology in Hospice and Palliative Medicine, Gynecologic Oncology and Obstetrics and Gynecology. He is a Fellow of the American Congress of Obstetrics and Gynecology and the American College of Surgeons. He is a member of the Society of Gynecologic Oncology and the American Society of Clinical Oncology. Dr. Timmins has been named a &ldquo;Top Doctor&rdquo; by Castle Connolly since 2013. In 2020, he was recognized as a Surgeon of Excellence in minimally invasive surgery by the Surgical Review Corporation. Dr. Timmins was recently elected to the Board of Governors of the American College of Surgeons.</p>

Is Open Scheduling

Off

Mark H. Einstein

https://assets.montefioreeinstein.org/profiles/images/Einstein_Mark_MD_2x.jpg

First Name

Mark

Last Name

Einstein

NPI

1356421812

Faculty ID

7382

CMO Specialties

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Gynecologic Oncology</p>
<p>Cervical Cancer</p>
<p>Immunotherapy</p>
<p>Clinical Trials</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4275

Biography

<p>Mark H. Einstein, MD, is the Chella & Moise Safra Endowed Chair and Department Chair, Obstetrics & Gynecology and Women&rsquo;s Health at Montefiore Einstein and Professor, Obstetrics & Gynecology and Women&rsquo;s Health at our Albert Einstein College of Medicine. Dr. Einstein is an internationally renowned expert in gynecologic oncology and gynecologic cancer prevention. He is very active clinically and manages complicated gynecologic precancers and malignancies using state-of-the-art evidence-based clinical and surgical strategies. He also leads and offers clinical trial options.</p><p>Throughout his career, Dr. Einstein has demonstrated his commitment to caring for patient populations, with direct experience and success as a clinician, surgeon-scientist, educator, mentor, and administrator. He is internationally acclaimed as a clinician-scientist and brings a national leadership profile that will help sustain Montefiore Einstein&rsquo;s stature as a top-rated and highly respected academic medical center.</p><p>After completing a combined BS/MD program at the University of Miami in 1995, Dr. Einstein completed a residency in obstetrics & gynecology at Saint Barnabas Medical Center in New Jersey in 1999. He completed a fellowship in gynecologic oncology at Montefiore Einstein in 2002, then stayed on as faculty as a clinician and researcher and, early in his career, he earned his Master of Science in clinical research methods in 2005.</p><p>Dr. Einstein&rsquo;s research focuses on the human papillomavirus (HPV). He has been principal investigator and co-investigator on numerous funded research projects and clinical trials and his work has been published in over 140 peer-reviewed publications. Dr. Einstein has also given numerous invited presentations nationally and internationally, and is a reviewer for several scientific journals.</p><p>As a surgical specialist who has mentored dozens of junior faculty, Dr. Einstein has a long track record of appreciation for the contributions of faculty who come from all training and demographic backgrounds. He is firmly committed to a culture of mutual respect and support, advocating its critical role in a health system&rsquo;s success. Additionally, as a surgeon and scientist, he has a results-proven track record of his collaborative ability to operationalize translational medicine teams and clinical programs across disciplines.</p><p>Dr. Einstein is board certified by the American Board of Obstetrics and Gynecology in General Obstetrics and Gynecology and Gynecologic Oncology. He is a Fellow of the American College of Obstetrics and Gynecology (ACOG) and the American College of Surgeons (ACS). He holds and has held many leadership roles in the Society of Gynecologic Oncologists (SGO), The American College of Obstetrics and Gynecology (ACOG), and the Society of Lower Genital Tract Diseases (ASCCP). He is also an examiner for the American Board of Obstetrics.</p>

Is Open Scheduling

Off

Theofano Orfanelli

https://assets.montefioreeinstein.org/profiles/images/Orfanelli_Theofano_MD_2x_v2.jpg

First Name

Theofano

Last Name

Orfanelli

NPI

1396188611

Faculty ID

17918

CMO Specialties

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

P1009689

Is Open Scheduling

Off

Anne R. Van Arsdale

https://assets.montefioreeinstein.org/profiles/images/Van_Arsdale_Anne_2x.jpg

First Name

Anne

Last Name

Van Arsdale

NPI

1407015183

Faculty ID

13210

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Clinical focus on a specialized colposcopy clinic for the diagnosis and treatment of cervical dysplasias.

Research Focus

Dr. Van Arsdale&rsquo;s research follows her clinical focus on gynecologic malignancies. Her focus is translational research of HPV integration as a biomarker for progressive cervical dysplasia and cervical carcinoma.&nbsp;

Elsevier Profile

EMR ID

4726

Biography

<p>Anne Van Arsdale, MD, MSc, is an attending physician and Associate Professor, Genetics and Obstetrics &amp; Gynecology and Women&rsquo;s Health at Montefiore Einstein. She treats all gynecologic malignancies, with a focus on a specialized colposcopy clinic for the diagnosis and treatment of cervical dysplasias.</p><p>After receiving her Bachelor of Science at Georgetown University in 2001, Dr. Van Arsdale attended Columbia University, earning her Doctor of Medicine in 2005. She came to Montefiore Einstein to begin her postdoctoral training with a four-year residency in obstetrics and gynecology. After completing her residency in 2009, she attended the London School of Hygiene and Tropical Medicine in London, England, earning her Master of Science in medical statistics. Dr. Van Arsdale then returned to Montefiore Einstein to pursue a three-year fellowship in gynecologic oncology, which she completed in 2016.</p><p>Dr. Van Arsdale&rsquo;s research follows her clinical focus on gynecologic malignancies. Her focus is translational research of HPV integration as a biomarker for progressive cervical dysplasia and cervical carcinoma. She is the current institutional principal investigator (PI) of the gynecologic tissue biorepository and the lead institutional PI for phase 2 and phase 3 trials for Inovio pharmaceuticals evaluating HPV therapeutic vaccination for the treatment of high grade cervical and vulvar dysplasia. Her research has been published in numerous peer-reviewed journals, abstracts and posters, and she is an ad hoc reviewer for several publications including <em>Frontiers Oncology, Gynecologic Oncology</em> and the <em>Journal of Lower Genital Tract Disease</em>.</p><p>Dr. Van Arsdale is board certified and a member of several professional organizations including the Society of Gynecologic Oncology, the American Society of Clinical Oncology and the American Association of Cancer Research. She has been the recipient of multiple internal and external award mechanisms, including the ME Strong Award from the Foundation of Women&rsquo;s Cancer, a Dew Point Scholar (Department of Obstetrics &amp; Gynecology and Women&rsquo;s Health), an American Association of Obstetricians and Gynecologists Foundation (AAOGF) Scholar, the National Cancer Institute (NCI) Early Surgeon Scientist Program (ESSP) Award and an NCI K08 award.</p>

Is Open Scheduling

Off

Nicole S. Nevadunsky

https://assets.montefioreeinstein.org/profiles/images/Nevadunsky_NIcole_MD_2x.jpg

First Name

Nicole

Last Name

Nevadunsky

NPI

1619131430

Faculty ID

11884

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Comprehensive care of women with uterine, cervical, and vulvar cancers. &nbsp;Interests include minimally invasive and robotic techniques.&nbsp;</p>

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Nicole Nevadunsky conducts translational research that enables her to deliver the highest quality care for her patients. She specializes in the prevention and treatment of gynecologic cancers. Recent clinical studies have evaluated palliative care in improving quality of life in patients with high risk primary or recurrent gynecologic malignancies; and physical activity interventions for endometrial cancer survivors.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5257

Is Open Scheduling

Off

Sharmila K. Makhija

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/a2294ee0-90d6-11ec-9364-af8bcc6a3d17.jpg

First Name

Sharmila

Last Name

Makhija

NPI

1063463131

Faculty ID

14588

CMO Specialties

Employment Status

Voluntary

Patient Type

Adult

Department

Gender

Female

Titles

Locations

Education and Trainings

Professional Interests

<p>Sharmila Makhija, MD, MBA, an international expert on gynecologic cancer, currently serves as Department Chair of Obstetrics &amp; Gynecology and Women&rsquo;s Health, professor of gynecologic oncology, and the The Chella and Moise Safra Endowed Chair at the Albert Einstein College of Medicine and Montefiore Medical Health System.&nbsp;</p>
<p>&nbsp;Dr. Makhija earned her B.A. in chemistry from Cornell University, medical degree from the University of Alabama at Birmingham and completed her obstetrics and gynecology residency at the University of Louisville Hospital and a fellowship in gynecologic oncology at Memorial Sloan‐Kettering Cancer Center in New York. She received her executive MBA from Emory&rsquo;s Goizueta Business School.</p>
<p>&nbsp;She has published and lectured nationally and internationally on developmental therapeutics for the treatment of ovarian cancer, for which she was named a NIH Women&rsquo;s Reproductive Health Research Scholar. Dr. Makhija is a graduate of the ELAM program an serves on numerous boards including Women&rsquo;s Voices For Change.</p>
<p>Dr. Makhija has received teaching awards, listed as a &ldquo;Top Doctor in America&rdquo; and named in Louisville&rsquo;s <em>Business First</em>, 2013 and 2014, Partners in Health Care as a &ldquo;Person to Watch&rdquo; for business leadership in healthcare.</p>

Research Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<div class="WordSection1">
<p><strong>Makhija S</strong>, Spanos WJ Jr, Day TG Jr, Doering D. CA-125 levels after surgical exploration and</p>
<p>radioactive chromic phosphate in ovarian cancer patients. <em>Gynecol Oncol</em>. 63(1):85-8, Oct 1996.</p>
<p>&nbsp;</p>
<p><strong>Makhija S</strong>, Taylor DD, Gibb RK, Gercel-Taylor C. Taxol-induced b cl -2 phosphorylation in</p>
<p>ovarian cancer cell monolayer and spheroids. <em>Int J of Oncol</em>. 14(3):515-21, Mar 1999.</p>
<p>&nbsp;</p>
<p><strong>Makhija S</strong>, Sabbatini P, Aghajanian C, Venkatraman V, Spriggs DR, Barakat R.</p>
<p>Intraperitoneal cisplatin and intravenous taxol in the treatment of epithelial ovarian cancer patients</p>
<p>with a positive second look. <em>Gynecol Oncol</em>. 79(1):28-32, Oct 2000.</p>
<p>&nbsp;</p>
<p><strong>Makhija S</strong>, Leitao M, Sabbatini P, Bellin N, Almadrones L, Leon L, Spriggs DR, Barakat R.</p>
<p>Complications associated with intraperitoneal chemotherapy catheters. <em>Gynecol Oncol</em>.</p>
<p>81(1):77-81, Apr 2001.</p>
<p>&nbsp;</p>
<p><strong>Makhija S</strong>, Howden N, Edwards R, Kelley J, Townsend DW , Meltzer CC.</p>
<p>Positron emission tomography/computer tomography imaging for the detection of recurrent</p>
<p>ovarian and fallopian tube carcinoma: a retrospective review. <em>Gynecol Oncol</em>. 85(1):53-8,</p>
<p>Apr 2002.</p>
<p>&nbsp;</p>
<p>Ohtsuka T, Buchsbaum D, Oliver P, <strong>Makhija S</strong>, Kimberly R, Zhou T. Synergistic induction of</p>
<p>tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38</p>
<p>and mitochondrial death pathway. <em>Oncogene</em>. 22(13):2034-44, Apr 2003.</p>
<p>&nbsp;</p>
<p><strong>Makhija S</strong>, Sit A, Edwards R, Aufman K, Weiss H, Kanbour-Shakir A, Gooding B, D&rsquo;Angelo G,</p>
<p>Ferrell R, Raja S, Godfrey T. Identification of genetic alterations related to chemoresistance in</p>
<p>epithelial ovarian cancer. <em>Gynecol Oncol</em>. 90(1):39, Jul 2003 (Lead Article)</p>
<p>&nbsp;</p>
<p>Zhu ZB, <strong>Makhija SK</strong>, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti</p>
<p>PJ, Leath CA, Yamamoto M, Alvarez RF, Curiel DT. Transcriptional targeting of adenoviral vector</p>
<p>through the CXCR4 tumor specific promoter. <em>Gene Therapy</em>. 11(7):645-8, Apr 2004.</p>
<p>Sharmila Makhija, MD, MBA,</p>
<p>&nbsp;</p>
<p>Zhu Z, <strong>Makhija SK</strong>, Lu B, Wang M, Kaliberova L, Liu B, Rivera A, Nettelbeck D, Mahasreshti P,</p>
<p>Leath C, Barker S, Yamamoto M, Li F, Alvarez R, Curiel D. Transcriptionally targeting tumor</p>
<p>with a novel tumor-specific promoter, the survivin promoter. <em>Cancer Gene Therapy</em>. 11(7):645-</p>
<p>8, Apr 2004.</p>
<p>&nbsp;</p>
<p>Zhu ZB, <strong>Makhija SK</strong>, Lu B, Wang M, Rivera AA, Preuss M, Zhou F, Siegal GP, Alvarez RD,</p>
<p>Curiel DT. Transport across a polarized monolayer of Caco-2 cells by transferring receptormediated</p>
<p>adenovirus transcytosis. <em>Virology</em>. 325 (1):116-28, Jul 2004.</p>
<p>&nbsp;</p>
<p>Lu B, <strong>Makhija SK</strong>, Nettelbeck DM, Rivera AM, Wang M, Komarova S, Zhou F, Yamamoto M,</p>
<p>Haisma HJ, Alvarez RD, Curiel DT, Zhu ZB. Evaluation of tumor-specific promoter activities in</p>
<p>melanoma. <em>Gene Therapy. </em>12(4):330-8, Feb 2005.</p>
<p>&nbsp;</p>
<p>Sahasrabuddhe V, <strong>Makhija S</strong>. Double jeopardy: HIV and cervical cancer in Indian women.</p>
<p><em>Int J of Gyn Cancer. </em>15(1):1-3, Jan-Feb 2005.</p>
<p>&nbsp;</p>
<p>&nbsp;Rocconi R, <strong>Makhija S</strong>, Alvarez R. Emerging therapeutic options for patients with</p>
<p>chemoresistant recurrent ovarian cancer: A literature analysis. <em>New Oncology: Ovarian</em></p>
<p><em>Cancer. </em>1(1):10-15, 2005.</p>
<p>&nbsp;</p>
<p>Rocconi R, Numnum T, Stoff-Khalili M, <strong>Makhija S</strong>, Alvarez R, Curiel D. Targeted gene</p>
<p>therapy for ovarian cancer. <em>Current Gene Therapy</em>. 5(6):643-53, Dec 2005 Review.</p>
<p>&nbsp;</p>
<p>&nbsp;Zhu ZB, <strong>Makhija SK</strong>, Lu B, Wang M, Rivera AA, Kim-Park S, Ulasov IV, Zhou F, Alvarez</p>
<p>RD, Siegal G, Curiel DT. Incorporating the survivin promoter in an infectivity enhanced</p>
<p>CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo. <em>Int J Oncol.</em></p>
<p>27(1):237-46, Jul 2005.</p>
<p>&nbsp;</p>
<p>Rocconi R, Numnum M, Zhu A, Lu Baogen, Wang M, Rivera A, Stoff-Khalili M, Alvarez R,</p>
<p>Curiel DT, <strong>Makhija S.</strong> Icodextrin enhances survival in an intraperitoneal ovarian cancer</p>
<p>murine model utilizing gene therapy. <em>Gynecol Oncol</em>. 12(103):985-89, Dec 2006. <em>Epub </em>Jul</p>
<p>20, 2006.</p>
<p>&nbsp;</p>
<p>Li Y, Wang H, Wang Z, <strong>Makhija S</strong>, Buchsbaum D, LoBuglio A, Kimberly R, Zhou T.</p>
<p>Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing</p>
<p>ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain</p>
<p>function. <em>Cancer Res. </em>66(17):8520-8 Sep 2006.</p>
<p>&nbsp;</p>
<p>Zhu ZB, Chen Y, <strong>Makhija S</strong>, Lu B, Wang M, Rivera AA, Yamamoto M, Wang S, Siegal</p>
<p>GP, Curiel DT, McDonald JM. Survivin promoter-based conditionally replicative</p>
<p>adenoviruses target cholangiocarcinoma. <em>Int J Oncol. </em>29(5):1319-29, Nov 2006.</p>
<p>&nbsp;</p>
<p>Zhu ZB, <strong>Makhija SK</strong>, Lu B, Wang M, Wang S, Takayama K, Siegal GP, Reynolds PN,</p>
<p>Curiel DT. Targeting mesothelioma using an infectivity enhanced survivin-conditionally</p>
<p>replicative adenoviruses. <em>J Thorac Oncol. </em>1(7):701-11, Sep 2006.</p>
<p>&nbsp;</p>
<p>Zhu ZB, Rivera AA, <strong>Makhija S</strong>, Lu B, Wang M, Izumi M, Cerfolio RJ, Stoff-Khalili MA, Zhou</p>
<p>F, Takayama K, Siegal GP, Curiel DT. Targeting lung cancer using an infectivity enhanced</p>
<p>CXCR4-CRAd. <em>Lung Cancer. </em>55(2):145-56, Feb 2007.</p>
<p>&nbsp;</p>
<p>Rocconi RP, Zhu ZB, Stoff-Khalili M, Rivera AA, Lu B, Wang M, Alvarez RD, Curiel DT,</p>
<p>Makhija S. Treatment of ovarian cancer with a novel dual targeted conditionally replicative</p>
<p>adenovirus (CRAd). <em>Gynecol Oncol. </em>105(1):113-21, Apr 2007.</p>
<p><strong>Sharmila Makhija, MD, MBA</strong>,</p>
<p>&nbsp;</p>
<p>Page JG, Tian B, Schweikart K, Tomaszewski J, Harris R, Broadt T, Polley-Nelson J,</p>
<p>Noker PE, Wang M, <strong>Makhija S</strong>, Aurigemma R, Curiel DT, Alvarez RD. Identifying the</p>
<p>safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-</p>
<p>delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer. <em>Am J Obstet</em></p>
<p><em>Gynecol. </em>196(4):389,1-9, Apr 2007. <em>Epud </em>Nov 17, 2006.</p>
<p>&nbsp;</p>
<p>Zhu ZB, Mathis MJ, <strong>Makhija SK</strong>, Lu B, Wang M, Ji S, Rivera AA, Rosenthal EL, Siegal GP,</p>
<p>Curiel DT. Targeting of a conditionally replicative adenovirus agent to human squamous cell</p>
<p>carcinomas of the head and neck. <em>Int J Oncol. </em>31(5):1213-22, Nov 2007.</p>
<p>&nbsp;</p>
<p>Numnum TM, <strong>Makhija S</strong>, Lu B, Wang M, Rivera A, Stoff-Khalili M, Alvarez RD, Zhu ZB,</p>
<p>Curiel DT. Improved anti-tumor therapy based upon infectivity-enhanced adenoviral</p>
<p>delivery of RNA interference in ovarian carcinoma cell lines. <em>Gynecol Oncol. </em>108(1):34-41,</p>
<p>Jan 2008. <em>Epub </em>Dec 3, 2007.</p>
<p>&nbsp;</p>
<p>Zhu ZB, Lu B, Park M, <strong>Makhija S</strong>, Numnum T, Kendrick J, Wang M, Tsuruta Y, Fisher P,</p>
<p>Alvarez RD, Zhou F, Siegal G, W u H, Curiel DT. Development of an optimized conditionally</p>
<p>replicative adenoviral agent for ovarian cancer. <em>Int J Oncol. </em>32(6):1179-88, Jun 2008.</p>
<p>&nbsp;</p>
<p><strong>Makhija S</strong>. The limitation of risk-based strategies for vaccination of the 19-26 year-old</p>
<p>female population. <em>US Obstetrics and Gynecology. </em>3(2); 60-1, 2008.</p>
<p>&nbsp;</p>
<p><strong>Makhija S</strong>, Amler, L, Glenn D, Ueland F, Gold M, Dizon D, Paton V, Lin C-Y, Januario T, Ng K,</p>
<p>Strauss A, Kelsey S, Sliwkowski M, Matulonis U. Clinical activity of gemcitabine plus</p>
<p>pertuzumab in platinum-resistant ovarian cancer, fallopian tube, or primary peritoneal cancer.</p>
<p><em>J Clin Oncol. </em>1;28(7):1215-23, Mar 2010. <em>Epub </em>Nov 9, 2009.</p>
<p><em>&nbsp;</em></p>
<p>Spriggs DR, <strong>Makhija S</strong>. Ovarian Cancer Staging: Time for a Closer Look? <em>J Clin Oncol,</em></p>
<p>August 1998.</p>
<p>&nbsp;</p>
<p><strong>Makhija S</strong>, Sabbatini P, Barakat RR. Intraperitoneal chemotherapy strategies in the treatment</p>
<p>of ovarian cancer carcinoma. <em>Curr Opin Obstet Gynecol. </em>11(1):23-7, Feb 1999. Review.</p>
<p><strong>&nbsp;</strong></p>
<p><strong>Makhija S</strong>. Commentary: Tubal ligation and risk of ovarian cancer in carriers of BRCA1</p>
<p>or BRCA 2 mutations: a case control study. <em>Women&rsquo;s Oncology Review, </em>September</p>
<p>2001.</p>
<p>&nbsp;</p>
<p><strong>Makhija S</strong>, Townsend D, Meltzer C, Curiel D. Advances in ovarian cancer imaging: the positron</p>
<p>emission tomography / computed tomography (PET/CT). <em>W omen's Oncology Review. </em>2:129-133,</p>
<p>2002.</p>
<p>&nbsp;</p>
<p><strong><span style="text-decoration: underline;">Books, Chapters in books, and Review Articles</span></strong></p>
<p>&nbsp;</p>
<p><strong>Makhija S</strong>, Barakat R, Markman M, Hoskins WJ. Borderline tumors of the ovary.</p>
<p>In Raghavan D, Brecher M, Johnson D, Meropol N, Thigpen T (eds). <em>The Textbook of</em></p>
<p><em>Uncommon Cancer (2nd Ed), </em>John Wiley and Sons, 1999.</p>
<p>&nbsp;</p>
<p><strong>Makhija S</strong>, Barakat R. Surgical oncology: An algorithmic approach. In Saclarides TJ,</p>
<p>Millikan KW , Godellas CV (eds). <em>Endometrial Cancer. </em>2001.</p>
<p>&nbsp;</p>
<p><strong>Makhija S</strong>, Partridge E. Pelvic exenteration. In Sciarra J (ed), <em>Gynecology and Obstetrics.</em></p>
<p>Vol. No. 14, Chapter 10, 1-8 pp, 2003.</p>
<p>&nbsp;</p>
<p>&nbsp;Estes JM, Conner M, and <strong>Makhija S</strong>. A 59 year-old female with IIIC endometrial</p>
<p>carcinoma: Controversies and approaches to management. In DS Dizon and NA Rustum.</p>
<p><em>Gynecologic Cancer: Evidence-Based Multidisciplinary Management, </em>Sudbury, MA: Jones &amp;</p>
<p>Bartlett, 2007.</p>
<p>&nbsp;</p>
<p>&nbsp;<strong>Makhija S</strong>, Partridge E. Pelvic Exenteration. In Sciarra J (ed), <em>Gynecology and Obstetrics, </em>2008.</p>
<p>&nbsp;</p>
<p>&nbsp;Nadkarni N, Perez C, Tew W, <strong>Makhija S</strong>. Cervical cancer. In Pazdur R, Wagman L,</p>
<p>Camphausen K, Hoskins W (eds). <em>Cancer Management: A Multidisciplinary Approach. </em>(Ed.</p>
<p>12), Chapter 17, 441-474 pp, 2009.</p>
<p>&nbsp;</p>
<p>Gattoc, L, <strong>Makhija S</strong>. Radical hysterectomy. In Lubin MF, Dodson TF, Winawer N (eds).</p>
<p>Medical Management of the Surgical Patient: <em>A Textbook of Perioperative Medicine </em>(5th</p>
<p>Ed). Chapter 24.4, Cambridge University Press. 2011.</p>
<p>&nbsp;</p>
<p>Gattoc L, Perez C, Tew W, <strong>Makhija S</strong>. Cervical Cancer. In Pazdur R, Wagman L,</p>
<p>Camphausen K , Hoskins W (eds). <em>Cancer Management: A Multidisciplinary Approach.</em></p>
<p>(Ed 16). Chapter 17, 2014.</p>
</div>

EMR ID

75953

Is Open Scheduling

Off

Ken Yu Lin

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/ae8adbe0-54d0-11ed-9db0-413aa75b1837.jpg

First Name

Ken

Last Name

Lin

NPI

1063683936

Faculty ID

15774

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Radical cancer surgery and minimally invasive surgery using laparoscopy and the da Vinci robotic platform

Research Focus

The long-term objective of Dr. Lin&rsquo;s research is to develop immunotherapy and biomarker-driven targeted therapy for gynecologic cancers.&nbsp;

Elsevier Profile

EMR ID

13918

Biography

<p>Ken Yu Lin, MD, is an Associate Professor, Obstetrics & Gynecology and Women&rsquo;s Health at Montefiore Einstein. He provides comprehensive, compassionate evidence-based care for women with gynecologic cancers. Dr. Lin performs radical cancer surgery and minimally invasive surgery using laparoscopy and the da Vinci robotic platform.</p><p>After obtaining his Bachelor of Science in chemistry from Stanford University in 1997, Dr. Lin earned his Doctor of Philosophy in biochemistry and cell and molecular biology at Johns Hopkins University in 2006, where he performed research in tumor immunology. He received his Doctor of Medicine at Northwestern University in 2007 before completing an obstetrics & gynecology residency at Yale-New Haven Hospital in 2011. He then completed his gynecologic oncology fellowship at the University of Texas Southwestern Medical Center in 2015.</p><p>The long-term objective of Dr. Lin&rsquo;s research is to develop immunotherapy and biomarker-driven targeted therapy for gynecologic cancers. Through his collaborations with biomedical scientists and participation in NRG Oncology, Dr. Lin&rsquo;s research spans several areas. These include developing immunotherapy for ovarian cancer, the biology of uterine serous carcinoma and developing therapy for gynecologic cancers of less common histology, particularly ovarian clear cell carcinoma and carcinosarcoma. His work has been published in numerous peer-reviewed journals, books, chapters, articles and abstracts, including <em>Cancer Research</em>, <em>Cell</em>, and <em>Science Translational Medicine</em>.</p><p>Dr. Lin is board certified in Obstetrics & Gynecology and Gynecologic Oncology and is a member of the Society of Gynecologic Oncology. He participated in the Reproductive Scientist Development Program (RSDP) from 2015 to 2018 and won the Gynecological Oncology Group (GOG) Foundation Early Investigator Award in 2019. He serves on the NRG Oncology Rare Tumor Committee.</p>

Is Open Scheduling

Off

Sara S. Isani

https://assets.montefioreeinstein.org/profiles/images/Isani_Sara_MD_2x.jpg

First Name

Sara

Last Name

Isani

NPI

1992973275

Faculty ID

12996

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Gynecological Oncology</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Clinical focus is on pre-cancers and cancers of the reproductive tract. She performs specialized cancer surgery as well as chemotherapy management of these conditions, and also cares for women with hereditary syndromes that increase risk of gynecologic malignancy.

Research Focus

Dr. Isani&rsquo;s clinical research includes trials to improve cancer survival and quality of life for cancer patients, as well as issues related to access of care.

Elsevier Profile

EMR ID

45793

Biography

<p>Sara Isani, MD, is Attending Physician at Montefiore and Associate Professor of Obstetrics and Gynecology &amp; Women&rsquo;s Health at our Albert Einstein College of Medicine. Her clinical focus is on pre-cancers and cancers of the reproductive tract. She performs specialized cancer surgery as well as chemotherapy management of these conditions, and also cares for women with hereditary syndromes that increase risk of gynecologic malignancy.</p><p>In 2001, Dr. Isani received her Bachelor of Arts in Ecology and Evolutionary Biology from Princeton University. In 2002, she attended New York University School of Medicine, earning her Doctor of Medicine degree in 2006. She started her postgraduate training with an internship and residency in Obstetrics and Gynecology at Yale New Haven Hospital from 2006 to 2010. She then pursued a Gynecologic Oncology fellowship at Albert Einstein College of Medicine, completing the two-year fellowship in 2013.</p><p>Dr. Isani&rsquo;s clinical research includes trials to improve cancer survival and quality of life for cancer patients, as well as issues related to access of care. Her work has been published in peer-reviewed journals, book chapters and abstracts.</p><p>Dr. Isani is board certified in obstetrics and gynecology and gynecologic oncology. She is a member of the Society of Gynecologic Oncology and the American Congress of Obstetrics and Gynecology.</p>

Is Open Scheduling

Off

Matthew W. Cowan

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/c8c16ef0-5dc3-11ee-bca8-e9237785e4a3.jpg

First Name

Matthew

Last Name

Cowan

NPI

1780975706

Faculty ID

17065

CMO Specialties

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Clinical focus in minimally invasive robotic surgery and his clinical focus is the treatment of all types of gynecologic malignancies.

Research Focus

Dr. Cowan&rsquo;s clinical research focuses on the tumor microenvironment and immune profile of ovarian tumors. He has a special interest in medical education, and he is an active advocate for the development of more humanistic and collaborative approaches to medical education.&nbsp;

Elsevier Profile

EMR ID

163352

Biography

<p>Matthew Cowan, DO, is Assistant Professor, Obstetrics and Gynecology &amp; Women’s Health at Montefiore Einstein. He has expertise in minimally invasive robotic surgery and his clinical focus is the treatment of all types of gynecologic malignancies.</p>

<p>After completing his Bachelor of Science at The Ohio State University in 2006, Dr. Cowan attended Midwestern University, earning his Doctor of Osteopathy degree in 2011. After completing his obstetrics and gynecology residency at Wright State University in Ohio, he worked as a general obstetrician and gynecologist in the Chicago area for three years. During this time, he was also a research associate at the University of Chicago. In 2021, he completed fellowship training in gynecologic oncology at Northwestern University, choosing this specialty in part for the journey he takes with patients through their cancer treatment and survivorship.</p>

<p>Dr. Cowan’s clinical research focuses on the tumor microenvironment and immune profile of ovarian tumors. He has a special interest in medical education, and he is an active advocate for the development of more humanistic and collaborative approaches to medical education. Dr. Cowan is lead and co-author of articles published in Gynecologic Oncology and other peer-reviewed journals, and has been invited to give oral and poster presentations at Society of Gynecologic Oncology (SGO) Annual Meetings on women’s cancer.</p>

<p>Dr. Cowan is board certified in obstetrics & gynecology and board eligible for gynecologic oncology. He is a member of several professional organizations including the SGO and the American Academy of Gynecologic Laparoscopists.</p>

Is Open Scheduling

Off